Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

The suppression of SH3BGRL is important for v-Rel-mediated transformation

Oncogene volume 25, pages 756–768 (2006)Cite this article

Abstract

The v-rel oncogene is the most efficient transforming member of the Rel/NF-κB family of transcription factors. v-Rel induces avian and mammalian lymphoid cell tumors and transforms chicken embryo fibroblasts in culture by the aberrant regulation of genes under the control of Rel/NF-κB proteins. Here we report that the expression of SH3BGRL, a member of the SH3BGR (SH3 domain-binding glutamic acid-rich) family of proteins, is downregulated in v-Rel-expressing fibroblasts, lymphoid cells, and splenic tumor cells. Chromatin immunoprecipitation experiments demonstrated that v-Rel binds to the sh3bgrl promoter in transformed cells. Coexpression of SH3BGRL with v-Rel in primary splenic lymphocytes reduced the number of colonies formed by 76%. Mutations in the predicted SH3-binding domain of SH3BGRL abolished the suppressive effect on v-Rel transformation and resulted in colony numbers comparable to those formed by v-Rel alone. However, mutations in the predicted EVH1-binding domain of SH3BGRL only had a modest effect on suppression of v-Rel transformation. This study provides the first example of a gene that is downregulated in v-Rel-expressing cells that also plays a role in v-Rel transformation.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8

Accession codes

Accessions

GenBank/EMBL/DDBJ

References

  • Akiyama Y, Kato S . (1974). Biken J 17: 105–116.

  • Baba TW, Giroir BP, Humphries EH . (1985). Virology 144: 139–151.

  • Baldwin Jr AS . (1996). Annu Rev Immunol 14: 649–683.

  • Ball LJ, Jarchau T, Oschkinat H, Walter U . (2002). FEBS 513: 45–52.

  • Barth CF, Ewert DL, Olson WC, Humphries EH . (1990). J Virol 64: 6054–6062.

  • Barzik M, Carl UD, Schubert W-D, Frank R, Wehland J, Heinz DW . (2001). J Mol Biol 309: 155–169.

  • Berleth ES, Henn AD, Gurtoo HL, Wollman R, Alderfer JL, Mihich E et al. (2000). Int J Immunopharmacol 22: 1137–1142.

  • Berleth ES, Nadadur S, Henn AD, Eppolito C, Shiojiri S, Gurtoo HL et al. (1999). Cancer Res 59: 5497–5506.

  • Bonizzi G, Karin M . (2004). Trends Immunol 25: 280–288.

  • Bose Jr HR . (1992). Biochim Biophys Acta 1114: 1–17.

  • Bull P, Morley KL, Hoekstra MF, Hunter T, Verma IM . (1990). Mol Cell Biol 10: 5473–5485.

  • Cao Y, Karin M . (2003). J Mammary Gland Biol Neoplasia 8: 215–223.

  • Carrasco D, Rizzo CA, Dorfman K, Bravo R . (1996). EMBO J 15: 3640–3650.

  • Cesareni G, Panni S, Nardelli G, Castagnoli L . (2002). FEBS 513: 38–44.

  • Chen C, Okayama H . (1987). Mol Cell Biol 7: 2745–2752.

  • Chen F, Castranova V, Shi X . (2001). Am J Pathol 159: 387–397.

  • Cheng Q, Cant CA, Moll T, Hofer-Warbinek R, Wagner E, Birnstiel ML et al. (1994). J Biol Chem 269: 13551–13557.

  • Chiao PJ, Miyamoto S, Verma IM . (1994). Proc Natl Acad Sci USA 91: 28–32.

  • Cogswell PC, Guttridge DC, Funkhouser WK, Baldwin ASJ . (2000). Oncogene 19: 1123–1131.

  • Deindl E . (2001). Biotechniques 31: 1250–1252.

  • Denk A, Wirth T, Baumann B . (2000). Cytokine Growth Factor Rev 11: 303–320.

  • Dougherty JP, Temin HM . (1986). Mol Cell Biol 6: 4387–4395.

  • Dyer RB, Herzog NK . (1995). Biotechniques 19: 192–195.

  • Egeo A, Mazzocco M, Arrigo P, Vidal-Taboada JM, Oliva R, Pirola B et al. (1998). Biochem Biophys Res Commun 247: 302–306.

  • Franklin RB, Kang C-Y, Wan KM-M, Bose Jr HR . (1977). Virology 83: 313–321.

  • Fujii M, Minamino T, Nomura M, Miyamoto KI, Tanaka J, Seiki M . (1996). Oncogene 12: 2193–2202.

  • Gasparian AV, Yao YJ, Kowalczyk D, Lyakh LA, Karseladze A, Slaga TJ et al. (2002). J Cell Sci 115: 141–151.

  • Gilmore TD . (1995). Regulation of Rel transcription complexes. In: Goodbourn S (ed). Frontiers in Molecular Biology: Eukaryotic Transcription. Oxford, England: Oxford University Press, pp 104–133.

    Google Scholar 

  • Gilmore TD . (1999). Oncogene 18: 6925–6937.

  • Grabs D, Slepnev VI, Songyang Z, David C, Lynch M, Cantley LC et al. (1997). J Biol Chem 272: 13419–13425.

  • Hayden MS, Ghosh S . (2004). Genes Dev 18: 2195–2224.

  • Henn AD, Berleth ES, Mihich E, Ehrke MJ . (2001). FASEB 15: 1315–1317.

  • Hrdlicková R, Nehyba J, Bose Jr HR . (1995a). J Virol 69: 3369–3380.

  • Hrdlicková R, Nehyba J, Bose Jr HR . (2001). Mol Cell Biol 21: 6369–6386.

  • Hrdlicková R, Nehyba J, Humphries EH . (1994). J Virol 68: 308–319.

  • Hrdlicková R, Nehyba J, Roy A, Humphries EH, Bose Jr HR . (1995b). J Virol 69: 403–413.

  • Kabrun N, Hodgson JW, Doemer M, Mak G, Franza Jr BR, Enrietto PJ . (1991). Proc Natl Acad Sci USA 88: 1783–1787.

  • Karin M, Cao Y, Greten FR, Li ZW . (2002). Nat Rev Cancer 2: 301–310.

  • Kerr LD, Inoue JI, Davis N, Link E, Baeuerle PA, Bose Jr HR et al. (1991). Genes Dev 5: 1464–1476.

  • Kralova J, Liss AS, Bargmann W, Bose Jr HR . (1998). Mol Cell Biol 18: 2997–3009.

  • Kralova J, Liss AS, Bargmann W, Pendleton C, Varadarajan J, Ulug E et al. (2002). J Virol 76: 11960–11970.

  • Kralova J, Schatzle JD, Liss AS, Bargman W, Bose Jr HR . (1996). Oncogene 12: 2595–2604.

  • Lee RM, Gillet G, Burnside J, Thomas SJ, Neiman P . (1999). Genes Dev 13: 718–728.

  • Li Q, Verma IM . (2002). Nat Rev Immunol 2: 725–734.

  • Liss AS, Bose Jr HR . (2002). J Virol 76: 4928–4939.

  • Madrid LV, Baldwin Jr AS . (2003). Methods Mol Biol 223: 523–532.

  • Mayer BJ . (2001). J Cell Sci 114: 1253–1263.

  • Mazzocco M, Arrigo P, Egeo A, Maffei M, Vergano A, Di Lisi R et al. (2001). Biochem Biophys Res Commun 285: 540–545.

  • Mazzocco M, Maffei M, Egeo A, Vergano A, Arrigo P, Di Lisi R et al. (2002). Gene 291: 233–239.

  • Mecham BH, Klus GT, Strovel J, Augustus M, Byrne D, Bozso P et al. (2004). Nucleic Acids Res 32: e74.

  • Moore BE, Bose Jr HR . (1988). Virology 162: 377–387.

  • Moore PA, Ruben SM, Rosen CA . (1993). Mol Cell Biol 13: 1666–1674.

  • Moscovici C, Zeller N, Moscovici MG . (1982). Continuous lines of AMV-transformed non-producer cells: growth and oncogenic potential in the chick embryo. In: Revoltella RF, Pontieri GM, Basiliico C, Rovera G, Gallo RC, Subak-Sharpe JH (eds). Expression of Differentiated Functions in Cancer Cells. Raven Press: New York, pp. 435–449.

    Google Scholar 

  • Nehyba J, Hrdličková R, Burnside J, Bose Jr HR . (2002). Mol Cell Biol 22: 3942–3957.

  • Nelson DM, Wahlfors JJ, Chen L, Onodera M, Morgan RA . (1998). Hum Gene Ther 9: 2401–2405.

  • Pahl HL . (1999). Oncogene 18: 6853–6866.

  • Petrenko O, Ischenko I, Enrietto PJ . (1997). Oncogene 15: 1671–1680.

  • Petsko G . (2002). Current Protocols in Bioinformatics. Hoboken: John Wiley & Sons, Inc.

    Google Scholar 

  • Rao A, Kline K, Sanders BG . (1990). Cancer Res 50: 4764–4770.

  • Romieu-Mourez R, Kim DW, Shin SM, Demicco EG, Landesman-Bollag E, Seldin DC et al. (2003). Mol Cell Biol 23: 5738–5754.

  • Sachdev S, Hannink M . (1998). Mol Cell Biol 18: 5445–5456.

  • Sambrook J, Fritsch EF, Maniatis T . (1989). Molecular Cloning: A Laboratory Manual, 2nd edn. Cold Spring Harbor: Cold Spring Harbor Laboratory Press.

    Google Scholar 

  • Sarkar S, Gilmore TD . (1993). Oncogene 8: 2245–2252.

  • Scartenzzini P, Egeo A, Colella S, Fumagalli P, Arrigo P, Nizetic D et al. (1997). Hum Genet 99: 387–392.

  • Schagger H, Jagow GV . (1987). Anal Biochem 166: 368–379.

  • Schatzle JD, Kralova J, Bose Jr HR . (1995). J Virol 69: 5383–5390.

  • Schwartz RC, Witte ON . (1988). Virology 165: 182–190.

  • Shi X-B, Ma A-H, Tepper CG, Xia L, Gregg JP, Gandour-Edwards R et al. (2004). Prostate 60: 257–271.

  • Sovak MA, Bellas RE, Kim DW, Zanieski GJ, Rogers AE, Traish AM et al. (1997). J Clin Invest 100: 2952–2960.

  • Stephens RM, Rice NR, Hiebsch RR, Bose Jr HR, Gilden RV . (1983). Proc Natl Acad Sci USA 80: 6229–6233.

  • Suh J, Payvandi F, Edelstein LC, Amenta PS, Zong WX, Gelinas C et al. (2002). Prostate 52: 183–200.

  • Suh J, Rabson AB . (2004). J Cell Biochem 91: 100–117.

  • Thalmann GN, Sikes RA, Wu TT, Degeorges A, Chang SM, Ozen M et al. (2000). Prostate 44: 91–103.

  • Tong AH, Evangelista M, Parsons AB, Xu H, Bader GD, Page N et al. (2001). Science 294: 2364–2368.

  • Tu JC, Xiao B, Yuan JP, Lanahan AA, Leoffert K, Li M et al. (1998). Neuron 4: 717–726.

  • White DW, Roy A, Gilmore TD . (1995). Oncogene 10: 857–868.

  • Wilhelmsen KC, Eggleton K, Temin HM . (1984). J Virol 52: 172–182.

  • You M, Bose Jr HR . (1998). Methods Enzymol 16: 373–385.

  • Zhang G, Slaughter C, Humphries EH . (1995). Mol Cell Biol 15: 1806–1816.

  • Zhang GQ, Humphries EH . (1996). Oncogene 12: 1153–1157.

  • Zhou JR, Yu L, Zerbini LF, Libermann TA, Blackburn GL . (2004). Int J Cancer 110: 800–806.

  • Zong W-X, Farrell M, Bash J, Gélinas C . (1997). Oncogene 15: 971–980.

Download references

Acknowledgements

We thank William Bargmann, Radmila Hrdlicková, Jarmila Kralova, Jiri Nehyba, and Emin Ulug for technical advice and critical reading of the manuscript. This work was supported by Public Health Service grant CA33192 from the National Cancer Institute.

Author information

Authors and Affiliations

  1. Section of Molecular Genetics and Microbiology, Institute of Cellular and Molecular Biology, University of Texas at Austin, Austin, TX, USA

    S M Majid, A S Liss & H R Bose Jr

  2. Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA

    M You

Authors
  1. S M Majid
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A S Liss
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M You
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H R Bose Jr
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H R Bose Jr.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Majid, S., Liss, A., You, M. et al. The suppression of SH3BGRL is important for v-Rel-mediated transformation. Oncogene 25, 756–768 (2006). https://doi.org/10.1038/sj.onc.1209107

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1209107

Keywords

  • v-Rel
  • NF-κB
  • SH3BGRL
  • SH3BGR
  • transformation

This article is cited by

Search

Advanced search

Quick links